TOPLINE:
GLP-1 receptor agonists (RAs) cut cardiovascular risks among patients with type 2 diabetes (T2D) and atopic dermatitis (AD) in this analysis.
METHODOLOGY:
- Analysis included 17,099 propensity score-matched patient pairs with T2D, with or without AD (mean age, 53 years; 67% women), in the TriNetX Linked network between 2015 and 2025, including pairs treated with GLP-1 RAs.
- About 36% of patients were White, 24% were Black, 5% were Asian, and 9% were Hispanic or Latino individuals.
- Primary outcomes included all-cause mortality, new-onset major adverse cardiovascular events (MACE), myocardial infarction (MI), heart failure, and ischemic stroke within 10 years.
TAKEAWAY:
- Patients with AD vs those without AD showed higher risks for MI (hazard ratio [HR], 1.17; P = .001), heart failure (HR, 1.36; P = .001), and ischemic stroke (HR, 1.32; P = .001), but not for MACE.
- Patients with AD had a significantly lower risk for mortality (HR, 0.67; P = .001) than those without AD.
- Among T2D patients with or without AD who were treated with GLP-1 RAs, no differences were seen in the risks for mortality, new-onset MACE, MI, heart failure, or stroke.
- Interaction analyses showed that GLP-1 RAs significantly reduced the risk for new-onset MACE (P = .043), MI (P = .015), heart failure (P = .007), and ischemic stroke (P = .003) in patients with AD and T2D.
IN PRACTICE:
“Among patients with T2D and AD, GLP-1 RAs significantly mitigated the risk of new-onset MACE, myocardial infarction, heart failure, and ischemic stroke compared to T2D controls without AD, suggesting that GLP-1 RAs may be effective options for reducing cardiovascular disease in this population,” the study authors wrote.
SOURCE:
The study was co-led by Natalie Braun, BA; Claire Lin, BA; Steven T. Chen, MD, MPH, MS-HPEd; and Kevin Sheng-Kai Ma, DDS, FRSPH, FRSM, Department of Dermatology, Massachusetts General Hospital, Boston. It was published online on August 18 in the Journal of the American Academy of Dermatology.
LIMITATIONS:
Limitations included the study’s retrospective design, reliance on billing codes, inability to control for GLP-1 RA treatment duration, and the shorter follow-up time in the GLP-1 RA-treated subgroups.
DISCLOSURES:
This study did not receive any funding, and the authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.